Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Join | Sign in
Home>Resources>Posters

  Posters

Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells: High Throughput and High Content Assessment of Cardiac Toxicity and Drug Efficacy by Monitoring Cytosolic Free Calcium Transients
1Kettenhofen R, 1Duenbostell A, 2Niedereichholz T, 3D’Angelo JM, 4Horai H, 5Schwengberg S, 1Bohlen H, 6Licher T"

Introduction of selected, pure human cardiomyocytes derived from induced pluripotent stem cell (hiPSCM) into a calcium transient imaging high throughput screening (HTS) assay to assess cardiotoxicity and drug efficacies.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.

Mixtures Analysis of Complex Mixtures
Michael Bernstein; Carlos Cobas; Santi Domínguez; Manuel Pérez; Agustín Barba

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds

MAB Discovery Technology: A Smart Way to Highly Diverse and Functional Therapeutic Antibodies
Hans-Willi Krell

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.

PRESEPSIN, A SOLUBLE CD14-SUBTYPE, A POSSIBLE NEW BIOMARKER INCREASES IN SEPTIC PATIENTS’ PLASMA FROM PEDIATRIC DEPARTMENT.
Hayato YAMAGUCHI1), Satoshi KIMURA1), Seiji FUKUOKA1), Emiko NAKAMA1), Hideyasu OTO2), Makoto INOUE2), Takashi SOGA2), Shigetaka KITAZAWA2), Yoh UMEDA2)

Increased plasma concentration of soluble CD14-subtype (presepsin) was observed in pediatric patients with bacteremia. Presepsin could be a possible biomarker of sepsis in pediatric patients, however, their reference interval in children could be lower than that of adults. More studies with larger number of samples are required to confirm the result.

A Novel Approach Toward Microfluidic Drug Metabolite Synthesis – Electrosynthetic Methodology Simulating Cytochrome (CYP450) Oxidation
Romain Stalder, Gregory P. Roth and Philip Podmore

A novel microfluidic technology and electrochemical synthesis method is demonstrated for the efficient generation of known drug metabolites. These metabolites are typically generated on first pass hepatic oxidation in vivo. The FLUX Module, a new microfluidic electrochemical cell manufactured by Syrris Ltd., has been employed to generate the metabolites of five commercial drugs: Tolbutamide, Chlorpromazine, Diclofenac, Primidone and Albendazole.

Exploring the Therapeutic Potential of a Peptide Derived from a Poxviral Immune Evasion Protein
Dylan Lawless

•9R-VIPER is an effective at TLR4 and TLR2 signal inhibition than VIPER.
•The structure of 9R-VIPER and the mutant peptide L6AE10A were investigated by NMR.
•Important structural information was uncovered and an explanation was found for the loss
of activity when important residues are changed.

On-chip quantification of miRNA using digital droplet PCR
Q. Cai1, R.S. Wiederkehr1, B. Jones1, B. Majeed1, T. Stakenborg1, P. Fiorini1, L. Lagae1, M Tsukuda2, T. Matsuno2, I. Yamashita2

miRNAs have a great potential in diagnostics. Hence, automated profiling of miRNAs are of great interest. In-house technology show that it is possible to implement a multiplexing assay for miRNAs on a microfluidic chip using digital droplet PCR.

<< 2 3 4 5 6 7 8 >>
Showing Results 41 - 50 of 188
Scientific News
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
New Clue to How Cancer Causes Organ Failure
New findings from a research group at Uppsala University show that the neutrophil, a type of blood cell, plays an important role in the process of induced organ failure.
Tackling Chemical Safety Rules and Regulations
Helsinki Chemicals Forum continues to lead international chemicals safety and management discussions.
Pioneering New Method to Map Enzyme Activity
Cardiff University researchers new discovery could have wide-reaching implications for the creation of manufactured goods, biofuels and therapeutic drugs.
Seashells to Deliver New Drugs and Vaccines
Australian scientists have developed a protective seashell-inspired capsule to preserve the active biological ingredients needed to create new drugs.
Euro Vision turns Reality for Australia’s Iconic ‘Green Whistle’
Patients will soon benefit from a unique invention, with emergency pain killer Penthrox receiving initial regulatory approval for sale in the European and UK markets.
New Type of Drug Can Target All Disease-causing Proteins
Current drugs block the actions of only about a quarter of known disease-causing proteins, but Yale University researchers have developed a technology capable of not just inhibiting, but destroying every protein it targets.
Laser Technique for Self-Assembly of Nanostructures
Researchers have developed a low-cost technique that holds promise for a range of scientific and technological applications.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters